Substitution management in opioid dependence

  • A. Uchtenhagen
Conference paper


Substitution treatment (replacement therapy) is the most widespread and the most frequently researched therapeutic approach to heroin dependence. At present, the “gold standard” is methadone maintenance, but the use of other agonists and of combined compounds with antagonists are increasingly used, especially Buprenorphine. This paper reviews the main findings from research and their consequences for best practice rules. The evolution and organisation of substitution treatment in Europe is described, indicating a major discrepancy in administrative regulations. Emerging trends are also mentioned, as well as the merits and limitations that mark the place of substitution treatment in a comprehensive therapeutic network for opioid dependence.


Methadone Maintenance Treatment Opioid Dependence Psychosocial Care Substitution Treatment Urine Control 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arif A, Westermeyer J (1990) Methadone maintenance in the management of opioid dependence. An international review. Praeger, New YorkGoogle Scholar
  2. Ali R, Auriacombe M, Casas M, Cottier L, Farrell M, Kleiber D, Kreuzer A, Ogborne A, Rehm J, Ward P (1998) Report of the external panel on the evaluation of the Swiss scientific studies of medically prescribed narcotics to drug addicts. Report to World Health Organisation, GenevaGoogle Scholar
  3. Amass L, Kamien JB, Mikulich SK (2000) Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug Alcohol Depend 58: 143–152PubMedCrossRefGoogle Scholar
  4. Amass L, Kamien JB, Mikulich SK (2001) Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opiate-dependent humans. Drug Alcohol Depend 61: 173–181PubMedCrossRefGoogle Scholar
  5. Ball JC, Ross A (1991) The effectiveness of methadone maintenance treatment. Springer, New YorkCrossRefGoogle Scholar
  6. Bammer G, Dobler-Mikola A, Fleming PH, Strang J, Uchtenhagen A (1999) The heroin prescribing debate: integrating science and politics. Science 284: 1277–1278PubMedCrossRefGoogle Scholar
  7. Bertschy G (1995) Pratique des traitements à 1a méthadone, Masson, ParisGoogle Scholar
  8. Best D, Harris J, Gossop M, Farrell M, Finch E, Noble A, Strang J (2000) Use of non-prescribed methadone and other illicit drugs during methadone maintenance treatment. Drug Alcohol Rev 19: 9–16CrossRefGoogle Scholar
  9. Brussel G van (1995) Le programme de distribution de morphine a Amsterdam: experiences pratiques. In: Rihs-Middel M, Clerc J, Stamm R (eds) La préscription de stupéfiants sous contrôle médical. Editions Médecine et Hygiène, Genève, pp 161–167Google Scholar
  10. Bühringer G, Gastpar M, Heinz W, Kovar KA, Ladewig D, Naber D, Täschner KL, Uchtenhagen A, Wanke K (1995) Methadon-Standards. Vorschläge zur Qualitätssicherung bei der Methadonsubstitutionim Rahmen der Behandlung von Drogenabhängigen. Enke, StuttgartGoogle Scholar
  11. Calsyn DS, Wells EA, Saxon AJ, Jackson TR, Wrede AF, Stanton V, Fleming C (1994) Contingency management of urinalysis results and intensity of counseling services have an interactive impact on methadone maintenance treatment outcome. J Addict Dis 13: 47–63PubMedCrossRefGoogle Scholar
  12. Caplehorn JR (1994) A comparison of abstinence-oriented and indefinite methadone maintenance treatment. Int J Addict 29: 1361–1375PubMedGoogle Scholar
  13. Chadderton A (2000) Clinical issues in using buprenorphine in the treatment of opiate dependence. Drug Alc Rev 19: 329–335CrossRefGoogle Scholar
  14. Chutuape MA, Silverman K, Stitzer ML (1998) Survey assessment of methadone treatment services as reinforcers. Am J Drug Alcohol Abuse 24: 1–16PubMedCrossRefGoogle Scholar
  15. Cooper JR, Altman F, Brown BS, Czechowicz D (1983) Research on the treatment of narcotic addiction. The state of the art. National Institute on Drug Abuse, RockvilleGoogle Scholar
  16. Dees SM, Dansereau DF, Simpson DD (1997) Mapping-enhanced drug abuse counseling: urinalysis results in the first year of methadone treatment. J Subst Abuse Treat 14: 45–54PubMedCrossRefGoogle Scholar
  17. Dolan K, Hall W, Wodak A (1998) The provision of methadone within prison settings. In: Ward J, Mattick RP, Hall W (eds) Methadone maintenance treatment and other opioid replacement therapies. Harwood, Amsterdam, pp 379–396Google Scholar
  18. Dole V, Nyswander M (1965) A medical treatment for Diacetylmorphine (heroin) addiction. JAMA 193: 146–150CrossRefGoogle Scholar
  19. Elkashef A (2002) Medications for the treatment of opiate dependence in the US. Current therapies and new developments. Communication in WHO Meeting, April 2002Google Scholar
  20. EMCDDA (2000) Reviewing current practice in drug-substitution treatment in the European Union. European Monitoring Centre for Drugs and Drug Addiction EMCDDA, LisbonGoogle Scholar
  21. EMEA (2001) Public statement on the recommendation to suspend the marketing authorisation for Orlaam in the European Union. European Agency for the Evaluation of Medicinal Products, LondonGoogle Scholar
  22. Finnegan LP, Hagan T, Kaltenbach KA (1991) Scientific foundation of clinical practice: opiate use in pregnant women. Bull NY Acad Med 67: 223–239Google Scholar
  23. Fudala PJ, Yu E, Macfadden W, Boardman C, Ciang CN (1998) Effects of buprenorphine and naloxone in morphine-stabilised opioid addicts. Drug Alcohol Depend 50: 1–8PubMedCrossRefGoogle Scholar
  24. Gossop M (1998) NTORS at one year. The National Treatment Outcome Research Study. Department of Health, LondonGoogle Scholar
  25. Hartnoll R, Mitcheson M, Battersby A, Brown G, Ellis M, Fleming P, Hedley N (1980) Evaluation of heroin maintenance in a controlled trial. Arch Gen Psychiatry 37: 877–884PubMedCrossRefGoogle Scholar
  26. Hubbard RL, Marsden ME, Rachal JV, Haarwood HJ, Cavanaugh ER, Ginzburg HM (1989) Drug abuse treatment. A national study of effectiveness. University of North Carolina Press, Chapel HillGoogle Scholar
  27. Kreek MJ (1996) Long-term pharmacotherapy for opiate (primarily heroin) addiction: opioid agonists. In: Schuster CH, Kuhar MJ (eds) Pharmacological aspects of drug dependence. Toward an integrated neurobehavioral approach. Springer, Berlin Heidelberg New York Tokyo, pp 487–562Google Scholar
  28. Lifschitz MH, Wilson GS, Smith EO, Desmond MM (1985) Factors affecting head growth and intellectual function in children of drug addicts. Pediatrics 75: 269–274PubMedGoogle Scholar
  29. Ling W, Klett JC, Gillis RC (1980) A cooperative clinical study of methadyl acetate. Arch Gen Psychiatry 37: 908–911PubMedCrossRefGoogle Scholar
  30. McLellan AT, Arndt IO, Metzger IS, Woody GE, O’Brien CP (1993) The effects of psychosocial services in substance abuse treatment. JAMA 269:1953–1959PubMedCrossRefGoogle Scholar
  31. Maddux JF, Desmond DP, Esquivel M (1995) Rapid admission and retention on methadone. Am J Drug Alcohol Abuse 21: 533–547PubMedCrossRefGoogle Scholar
  32. Mattick RP, Oliphant D, Ward J, Hall W (1998) The effectiveness of other opioid replacement therapies: LAAM, Heroin, Buprenorphine, Naltrexone and injectable maintenance. In: Ward J, Mattick RP, Hall W (eds) Methadone maintenance treatment and other opioid replacement therapies. Harwood, Amsterdam, pp 123–160Google Scholar
  33. Mendelson J, Jones RT, Welm S, Baggott M, Fernandez I, Melby AK, Nath RP (1999) Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilised, opiate dependent volunteers. Psychopharmacology 141: 37–46PubMedCrossRefGoogle Scholar
  34. Metrebian N, Shanahan W, Wells B, Stimson GV (1998) Feasibility of prescribing injectable heroin and methadone to opiate-dependent drug users: associated health gains and harm reductions. Med J Aust 168: 596–600PubMedGoogle Scholar
  35. Mino A (1990) Analyse scientifique de la litérature sur la remise contrôlée d’héroïne ou de morphine. Institutions universitaires de psychiatrie, GenèveGoogle Scholar
  36. National Institute of Drug Abuse NIDA (1999) Principles of drug addiction treatment. A research-based guide. National Institute of Drug Abuse, National Institutes of Health, Bethesda, MDGoogle Scholar
  37. National Institutes of Health NIH (1998) National consensus development panel on effective medical treatment of opiate addiction. JAMA 280: 1936–1943CrossRefGoogle Scholar
  38. Parrino MW (1991) State Methadone Treatment Guidelines. U.S. Department of Health and Human Services, RockvilleGoogle Scholar
  39. Raschke P (1994) Substitutionstherapie. Ergebnisse langfristiger Behandlung von Opiatabhängigen. Lambertus, Freiburg im BreisgauGoogle Scholar
  40. Rhee JM van (1998) Study on the effectiveness of medically coprescribed heroin. Progress report. Central Committee on the Treatment of Heroin Addicts, UtrechtGoogle Scholar
  41. Rhoades HM, Creson D, Elk R, Schmitz J, Grabowsk J (1998) Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency. Am J Publ Health 88: 34–39CrossRefGoogle Scholar
  42. Robinson GM, Dukes PD, Robinson BJ, Cook RR, Mahoney GN (1993) The misuse of buprenorphine and buprenorphine-naloxone combination in Wellington, New Zealand. Drug Alcohol Depend 33: 81–86PubMedCrossRefGoogle Scholar
  43. Ruel JM (1996) International survey on the use of methadone in the treatment of narcotic addiction. Bureau of Drug Surveillance, Ottawa, CanadaGoogle Scholar
  44. Savage C, Karp EG, Curran SF, Hanlon TE, McCabe OL (1976) Methadone/LAAM maintenance: a comparison study. Compr Psychiatry 17: 415–424PubMedCrossRefGoogle Scholar
  45. Scott RTA, Jay MJH, Keith R, Oliver JS, Cassidy MT (1999) A confidential enquiry into methadone-related deaths. Addiction 94: 1789–1794PubMedCrossRefGoogle Scholar
  46. Seidenberg A, Honegger U (1998) Methadon, Heroin und andere Opioide. Medizinisches Manual für die ambulante opioidgestützte Behandlung. Huber, BernGoogle Scholar
  47. Senay EC, Uchtenhagen A (1990) Methadone in the treatment of opioid dependence. In: Arif A, Westermeyer J (eds) Methadone maintenance in the management of opioid dependence. Praeger, New York, pp 19–54Google Scholar
  48. Senay EC, Barthwell A, Marks R, Bokos PJ (1994) Medical maintenance: an interim report. J Addict Dis 13: 65–69PubMedCrossRefGoogle Scholar
  49. Simpson DD, Sells SB (1990) Opioid addiction and treatment: a 12-year follow-up. Krieger, MalabarGoogle Scholar
  50. Simpson DD, Curry SJ (eds) (1997) Drug Abuse Treatment Outcome Study DATOS. Psychol Addict Behav 11 (special issue)Google Scholar
  51. Simpson DD, Joe GW, Dansereau DF, Chatham LR (1997) Strategies for improving methadone treatment process and outcomes. J Drug Issues 27: 239–260Google Scholar
  52. Stitzer ML, Iguchi MY, Felch LJ (1992) Contingent take-home incentive: effects on drug use of methadone. J Consult Clin Psychol 60: 927–934PubMedCrossRefGoogle Scholar
  53. Strang J, Gossop M (1996) Heroin prescribing in the British system: a historical review. Eur Addict Res 2: 185–193CrossRefGoogle Scholar
  54. Svikis DS, Lee JH, Haug NA, Stitzer ML (1997) Attendance incentives for outpatient treatment: effects in methadone-and nonmethadone-maintained pregnant drug dependent women. Drug Alcohol Depend 48: 33–41PubMedCrossRefGoogle Scholar
  55. Tennant FS, Rawson RA, Pumphrey E, Seecof R (1986) Clinical experiences with 959 opioid-dependent patients treated with levo-alpha-acetylmethadol (LAAM). J Subst Abuse Treatment 3: 195–202CrossRefGoogle Scholar
  56. Uchtenhagen A, Zimmer-Höfler D (1985) Heroinabhängige und ihre normalen Altersgenossen. Herkunft, Lebenssituation, Zweijahresverlauf im Quervergleich. Haupt, BernGoogle Scholar
  57. Uchtenhagen A, Dobler-Mikola A, Steffen T, Gutzwiller F, Blättler R, Pfeifer S (1999) Prescription of narcotics for heroin addicts. Main results of the Swiss National Cohort Study. Karger, BaselGoogle Scholar
  58. Van den Brink W, Hendriks VM, Blanken P, Huijsman JA, van Ree JM (2002) Medical co-prescription of heroin. Two randomised controlled trials. Central Committee on the Treatment of Heroin Addicts, UtrechtGoogle Scholar
  59. Verthein U, Degkwitz P, Haasen C, Raschke P, Krausz M (1996) Die Substitutionsbehandlung Opiatabhängiger mit Codein/Dihydrocodein und Methadon — ein Kontrollgruppenvergleich. Sucht 42: 108–115Google Scholar
  60. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE (1994) Clinical pharmacology of buprenorphine. Ceiling effects at high doses. Clin Pharmacol Ther 55: 569–580PubMedCrossRefGoogle Scholar
  61. Ward J, Mattick R, Hall W (1998) Methadone maintenance treatment and other opioid replacement therapies. Harwood, AmsterdamGoogle Scholar
  62. Westermann B, Bellmann G, Jellinek C (eds) (2000) Beigebrauch: offene Grenzen der Substitution. Beltz, WeinheimGoogle Scholar
  63. Woody GE, McLellan AT, Luborsky LO, Brien CP Psychotherapy in community methadone programs: a validation study. Am J Psychiatry 152: 1302–1308Google Scholar
  64. World Health Organization (1989) Options for the use of methadone in the treatment of drug dependence. Geneva (WHO/MNH/DAT/89/2)Google Scholar
  65. World Health Organisation (1998) WHO Expert Committee on Drug Dependence. Thirtieth Report. WHO, Geneva (Technical Report Series 873)Google Scholar

Copyright information

© Springer-Verlag Wien 2003

Authors and Affiliations

  • A. Uchtenhagen
    • 1
  1. 1.Addiction Research InstituteZurichSwitzerland

Personalised recommendations